Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why do you own 150,000 shs of this stock?
Leo controls Leo. He and Menon have enuf stock and options to control.
New guy is handling day to day. Don't try to read too much into that response. Leo still controls the company
Youssef, CTIX at 1.50 is like buying a perpetual option
Musk has repeatedly overpromised about Tesla. Hasn't hurt his stock. Do people call him a liar? no. They call him a visionary
Could call that an odd shaped cup with handle
They have so much already. Why should they?
Leo, won't sell that cheap. Someone asked him for a valuation a while back. If I remember and he wasn't specific, he felt B is worth at least $5Billion and K he said look at other deals. So to me that means $15 Billion. IMHO he would need $20+ Billion to sell. And he has so much confidence in our drugs that he will wait. He said he would like to be like a Regeneron.
It is exactly the opposite.
Nice buy at 1.80. I guess you now become an investor rather than a trader
Leo already said he will do a partnership with P. He said he has a lot of interest.
ericseb I'm not guessing May 31. It's just that we all want instant gratification. Leo said May. Too many people pin him down and get disappointed when it's not the 1st or 2nd. It will come in the month of May. We are here for the long term score
So is may 31
It's exposure. Someone must buy it
New report out.
Osteoarthritis Pipeline Market H1 2016 Global Review Report
2:00 am ET April 28, 2016 (PR Newswire) Print
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this H1 2016 Osteoarthritis Pipeline report include A. Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., Addex Therapeutics Ltd, Akari Therapeutics, Plc, Amura Holdings Limited, Arcarios BV, Asahi Kasei Pharma Corp., Asklepios BioPharmaceutical, Inc., Astellas Pharma Inc., Asterias Biotherapeutics, Inc., Axsome Therapeutics, Inc., Biopharm GmbH, Can-Fite BioPharma Ltd., Cara Therapeutics, Inc., Cardax Pharmaceuticals, Inc., Cellceutix Corporation, Cellular Biomedicine Group, Inc., Chong Kun Dang Pharmaceutical Corp., D
Market making thieves
Scottsmith, where do I sign?
Resignation of Jorgensen. Has to raise questions,,,
No. I'm saying that Sullivan has to know all info both public and private in order ton defend the lawsuit properly.
No leaks. Leo said he will partner with good P results. Mako won't drop case and Judge will be very careful about ruling. Doesn't want to be overturned on appeal. P just ended. Results aren't available unless someone was following all the patients. Stock should be much higher on what is public info. Maybe late reaction to all the PR's
Ashcroft has a lot of faith in CTIX. I'm sure they know a lot more than either of us about trial results. Ashcroft is playing to make a real score.
Out of pocket reimbursement only.
Read the filings. One million shares at 1.70 option price for 3 years. Nothing about "if" or anything else. Ashcroft must have great confidence in what they saw. I am sure we are paying their out of pocket expenses.
Judge does not want her ruling overturned on appeal. She will let it play out
Rosen says they don't know Mako. lmao
Lawyers are taking stock options. Minimal cash
The report is $2,000
This is on TDAmeritrade news feed today
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Company Profiles discussed in this report includes Ability Pharma, SL, Acceleron Pharma, Inc., Advenchen Laboratories, LLC, Aeterna Zentaris Inc., Arno Therapeutics, Inc., ArQule, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., BeiGene(Beijing) Co.,Ltd, Boehringer Ingelheim GmbH, Cellceutix Corporation, Critical Outcome Technologies Inc., Eisai Co., Ltd., Eli Lilly and Company, Esperance Pharmaceuticals, Inc., Exelixis, Inc., Galena Biopharma, Inc., Genmab A/S, GlaxoSmithKline Plc, Gradalis Inc., ImmunoGen, Inc., Incyte Corporation, Karyopharm Therapeutics, Inc., Medivation, Inc., Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Novartis AG, OncoHoldings, Inc., Oncothyreon Inc., Otsuka Holdings Co., Ltd., Pharma Mar, S.A., Pharmsynthez, Puma Biotechnology, Inc., Sanofi, Scancell Holdings Plc and Shenogen Pharma Group Ltd. Complete report on H2 2015 pipeline review of Endometrial Cancer with 57 market data tables and 16 figures, spread across 280 pages is available at http://www.reportsnreports.com/reports/453485-endometrial-cancer-pipeline-review-h2-2015.html .
Drugs Profiles discussed in this report includes Pb-TCMC-Trastuzumab, ABTL-0812, AEZS-125, AL-3818, ARQ-092, AV-203, AZD-2014, AZD-5363, BGB-283, buparlisib hydrochloride, cabozantinib s-malate, cancer vaccine, Cell Therapy for Ovarian and Endometrial Cancer, Cell Therapy to Target HER-2 for Oncology, CLR-457, COTI-2, cridanimod, dalantercept, EP-200, epacadostat, everolimus, GALE-301, GSK-2636771, HO-3867, HuMax-TF-ADC, INCB-54828, KM-3174, lenvatinib, lurbinectedin, LY-3023414, mirvetuximab soravtansine, MK-2206, Modi-1, Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer, neratinib, nintedanib, onapristone ER, ONCO-101, ONT-10, OPB-111001, Peptides to Inhibit GnRH II Receptor for Oncology, pimasertib hydrochloride + voxtalisib, sapanisertib, SAR-408701, selinexor, Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma, SNG-1153, SP-2509, talazoparib, trametinib dimethyl sulfoxide + uprosertib, X-480 and zoptarelin doxorubicin.
Order a Purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=453485 .
Need dismissal of lawsuit before any move
Bear market in biotech and whole market for that matter
Bradley does not predict direction. Only an important point. Could be a top or bottom
Good article. Leo paid for it. It's a PR firm
My father also died from pancreatic cancer. Diagnosed with Stage 4, died about 3 months later.
Mayo Clinic :)
This is get me out at any price mentality. Small holders
Karin, someone here al ready tried sending something to the NY Bar and they said they don't act while pending litigation. Contact the Bar after the litigation ends.
Karin, someone here al ready tried sending something to the NY Car and they said they don't act while pending litigation. Contact the Bar after the litigation ends.
At least she could have said B is the answer
So wrong. Mako hit piece in concert with Rosen preconceived class action was a one two punch that hurt CTIX badly. Nothing to do with CEO. Stock is in the pink sheets badlands. Easily manipulated.
The lawsuit is also hanging over the sp. Bogus as it is it's a cloud.